AI, Evidence & Regulation in Pharma: From Discovery to Decision-Making
Sign up to join our exclusive eventAI is revolutionizing the pharmaceutical industry, delivering transformative results—from accelerating drug discovery to uncovering new therapies and streamlining workflows. But as AI adoption grows, so do the challenges of ensuring your data and content remain compliant, ethical, and aligned with regulatory standards.
Are you confident your organization is on the right side of regulation?
At this exclusive event, we’ll show you how to harness the power of AI while navigating the complex regulatory landscape. Our expertise in the pharmaceutical sector has demonstrated how trusted, compliant data can drive faster, better decisions—helping organizations like yours achieve superior patient outcomes while staying ahead of compliance challenges.
Taylor & Francis partners with all the large pharmaceutical companies to publish their latest research, support their R&D goals, and more recently, to ensure pharmaceutical companies have the right content for their AI tools. We are proud of our record of partnering with organizations in the pharmaceutical industry and this event, aimed at supporting regulatory professional navigate AI, is another example of how we can support industry meet their goals.
Confirm your attendance today.
Why Attend:
Day 1: Tuesday, June 2, 2026
We will give you access to CPHI Americas Conference where you can explore, learn and unlock opportunities around AI, its use within the pharmaceutical industry, and how to stary ahead of regulatory frameworks
Day 2: Agenda:
9:30 am (15 mins): Welcome & context
Why this conversation matters now: the rapid emergence of AI across pharmaceutical research, regulatory strategy, and scientific knowledge workflows
The importance of trusted evidence and multidisciplinary research in supporting reliable, compliant AI systems
What participants should gain: shared insights, peer perspectives, and a collaborative discussion on the future of AI in pharma
9:45 am (30 mins): AI and the future of regulatory science
How the FDA is evaluating the use of AI across drug development, regulatory submissions, and post-market oversight
Emerging expectations for data quality, validation, and transparency when AI supports regulatory decision making
How regulators view the role of AI in accelerating innovation while maintaining safety and scientific rigor
10:15 am (60 mins): What keeps pharmaceutical organizations up at night? Rolling out AI across an organization – a roundtable discussion
Where are you on the AI scale? Barriers & Concerns? What challenges do you face when scaling up the AI you use.
Learn from others in industry how they are tackling the same challenges
Break
11:30 am (60 mins): The next phase of AI in the pharmaceutical industry
Where the industry currently sits on the AI maturity curve
How regulatory expectations may shape the pace of adoption
Where AI will create the greatest impact across drug development and regulatory strategy
What collaboration across the ecosystem could accelerate progress
12:30 – 1:30 pm (60 mins) Lunch Break
1:30 pm (60 mins): Building the evidence layer for AI in regulatory science: roundtable discussion
How regulatory and knowledge teams evaluate the reliability of information used in AI-supported workflows
The role of peer-reviewed research and curated scientific knowledge in reducing hallucinations and improving traceability
What an “AI-ready” evidence infrastructure should look like for regulated pharmaceutical environments
2:30 pm (45 mins): Applying todays learning to our businesses
Licensing options
Routledge Academy
3:15 pm: Close & next steps
Round up of the day – key points
How T&F will support ongoing collaboration
Invitation to contribute to a follow‑up white paper or working group